Localisation of the bacteria the ileum of a mouse fed a standard diet (left) or a high-fat diet (right).
© Institut Pasteur
The billions of bacteria that populate our intestine – known as the microbiota – play a central role in digestion, but also have a role in some diseases such as type 2 diabetes or obesity. These diseases have often been associated with an imbalance of the intestinal flora, with some bacteria becoming clearly predominant, and a permeable intestine, likely to release inflammatory substances into the bloodstream. But although many studies have been conducted on the state of the microbiota once the disease has become established, few have focused on the development of this intestinal imbalance, e.g. when a high-fat diet is introduced. For this reason, an international research team has addressed the question. “We wanted to see, from an early stage, how the intestinal bacteria behave in the presence of a high-fat diet,” emphasises Thierry Pédron, a research engineer in the Molecular Microbial Pathogenesis Unit (Institut Pasteur/Inserm). “And we soon focused our research on the small intestine, because that was where we saw the most obvious variations!”
Some mice in the study were therefore fed an ordinary diet, whereas others were fed a diet containing 70% lipid. Using genomic techniques, the researchers were able to identify the different bacterial species contained in faecal samples, and monitor the changes in composition of the microbiota in time. They also localised and accurately identified the bacteria within the small intestine.
Ordinarily, bacteria cannot come close to or even cross the intestinal wall because the epithelium releases antimicrobial peptides and is lined with a protective mucus. The researchers then focused on these intestinal wall defences: they found that production of antimicrobial peptides fell following massive ingestion of fat, and that the mucus layer became thinner. In other words, not only does the microbiota become reorganised under the influence of lipids, but the intestine itself undergoes transformation. And the modifications do not end there. Additional measurements made it possible to demonstrate an increase in the permeability of the small intestine, and a reduction in PPAR-γ activity. “PPAR-γ is a molecule with many functions. It plays an important role in fatty acid metabolism, as well as in inflammation and embryonic development,” explains Thierry Pédron. “This drop seems closely related to the drop in antimicrobial peptide level.” And although the connections between all these results and their potential involvement in some dietary imbalances have not yet been established, it is reassuring to note that when the mice are put back on a balanced diet, everything returns to normal within a month!
Phage therapy involves the use of bacteriophages, or phages, for treating bacterial infections. Phages are viruses that specifically attack bacteria and are harmless to humans. A significant decline in the use of this therapeutic strategy introduced 100 years ago was seen in ...
Inserm researchers in Rouen (Unit 1234 "PANTHER: Physiopathology, autoimmunity, neuromuscular diseases and regenerative therapies", Inserm/Université de Rouen Normandie) have tested with success a cell therapy aiming to restore the ability of the sphincters to contract in patients with fecal incontinence. As part ...
High-fat diet modifies the PPAR-γ pathway leading to disruption of microbial and physiological ecosystem in murine small intestine, PNAS, 16 September 2016. DOI: 10.1073/pnas.1612559113
Julie Tomasa,b,c, Céline Muleta, Azadeh Saffariana, Jean-Baptiste Cavind, Robert Ducrocd, Béatrice Regnaulte, Chek Kun Tanf, Kalina Duszkaf, Rémy Burceling,h, Walter Wahlif,i, Philippe J. Sansonettia,j,1, and Thierry Pédrona
a Unité de Pathogénie Microbienne Moléculaire, INSERM Unit U1202, Institut Pasteur, 75724 Paris Cedex 15, France;
b Institut National de la Recherche Agronomique, UMR 1319 MICALIS, F-78350 Jouy-en-Josas, France;
c AgroParisTech, UMR 1319 MICALIS, F-78350 Jouy-en-Josas, France;
d INSERM UMRS 1149, Centre de Recherche sur l’inflammation, Unité de Formation et de Recherche de Medecine Paris Diderot, F-75018 Paris, France;
e Plate-forme de Génotypage des Eucaryotes, Biomics Pole, Centre d’Innovation et Recherche Technologique, Institut Pasteur, Paris F-75015, France;
f Lee Kong Chian School of Medicine,Nanyang Technological University, Singapore;
g Institut des Maladies Métaboliques et Cardiovasculaires, INSERM U1048 F-31432 Toulouse, France;
h Université Paul Sabatier, F-31432 Toulouse, France;
i Center for Integrative Genomics, University of Lausanne, 1015 Lausanne, Switzerland; and
j Chaire de Microbiologie et Maladies Infectieuses, Collège de France, 75005 Paris, France